Neuropathic pain and symptoms of potential small-fiber neuropathy in fibromyalgic patients: A national on-line survey

2021 ◽  
Vol 88 (4) ◽  
pp. 105153 ◽  
Author(s):  
Antonello Viceconti ◽  
Tommaso Geri ◽  
Simone De Luca ◽  
Filippo Maselli ◽  
Giacomo Rossettini ◽  
...  
Author(s):  
Aziz Shaibani

Sensory symptoms are the most common symptoms in neuromuscular clinics, yet it is hard to capture them via video unless they have a very specific pattern and they are associated with objective loss of sensation. Distal sensory loss is a common neuropathic finding. It follows gloves and stocks distribution. Sensory neuropathies may present with ataxia which results in falls, or severe pain. Neuropathic pain with normal ankle reflexes and sural responses suggest small fiber neuropathy. Multifocal sensory loss is usually vascular. It can also be infectious (leprosy). Migratory neuritis is a poorly understood condition. Intercostal pain and numbness is usually due to radiculopathy (diabetic, zoster, or compressive radiculopathy). Foots ulcers and unfelt mosquito bites are markers for sensory loss. Loss of corneal sensation may led to keratitis and blindness.


Nutrients ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 576 ◽  
Author(s):  
Michael L. Rosenberg ◽  
Vahid Tohidi ◽  
Karna Sherwood ◽  
Sujoy Gayen ◽  
Rosina Medel ◽  
...  

Peripheral neuropathies associated with painful small fiber neuropathy (SFN) are complex conditions, resistant to treatment with conventional medications. Previous clinical studies strongly support the use of dietary agmatine as a safe and effective treatment for neuropathic pain. Based on this evidence, we conducted an open-label consecutive case series study to evaluate the effectiveness of agmatine in neuropathies associated with painful SFN (Study Registry: ClinicalTrials.gov, System Identifier: NCT01524666). Participants diagnosed with painful SFN and autonomic dysfunctions were treated with 2.67 g/day agmatine sulfate (AgmaSet® capsules containing G-Agmatine® brand of agmatine sulfate) for a period of 2 months. Before the beginning (baseline) and at the end of the treatment period, participants answered the established 12-item neuropathic pain questionnaire specifically developed to distinguish symptoms associated with neuropathy and to quantify their severity. Secondary outcomes included other treatment options and a safety assessment. Twelve patients were recruited, and 11 patients—8 diagnosed with diabetic neuropathy, two with idiopathic neuropathy and one with inflammatory neuropathy—completed the study. All patients showed improvement in neuropathic pain to a varied extent. The average decrease in pain intensity was 26.0 rating points, corresponding to a 46.4% reduction in overall pain (p < 0.00001). The results suggest that dietary agmatine sulfate has a significant effect in reducing neuropathic pain intensity associated with painful SFN resistant to treatment with conventional neuropathic pain medications. Larger randomized placebo-controlled studies are expected to establish agmatine sulfate as a preferred treatment.


2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 474.1-474
Author(s):  
A. Viceconti ◽  
T. Geri ◽  
S. De Luca ◽  
F. Maselli ◽  
A. Sulli ◽  
...  

Background:Fibromyalgia (FM) is the second most frequent disorder in rheumatic patients. Other than widespread pain, fatigue, sleep disturbance and cognitive impairments, patients complain also symptoms of suspected neuropathic origin, like burning pain, thermal sensitive skin, hyperalgesia, pins and needles sensations. Recent studies highlighted the presence of small- fibers pathology (SFP) and/or large-nerve fibers involvement in about 50% of FM patients, which could be the cause of neuropathic pain.Objectives:The aim of the study was to investigate the prevalence of neuropathic pain and symptoms indicative for the presence of SFP in Italian FM patients, studying the association with clinical variables.Methods:An on-line survey was designed according to the Checklist for Reporting Results of Internet E-Surveys guidelines (CHERRIES) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). The on-line Survey Monkey® platform was adopted to collect data. We calculated a-priori minimum number of 800 responders.We administered the survey by involving 7 FM patients’ associations distributed nationwide between July and September 2019. We explored demographic and clinical variables including pain and stiffness intensity, symptoms duration, and counting of painful sites. Neuropathic Pain Symptoms Inventory (NPSI) and Fibromyalgia Impact Questionnaire (FIQ) were administered. To study the presence of symptoms indicative of potential SFP we asked for the presence of 8 signs and symptoms reported in literature as characteristics of SFPs. Two groups of FM patients were considered: those positive (FM+) to the Fibromyalgia Research Criteria (FRC) (Wolfe et al., 2011), and those complaining typical FM symptoms but not fulfilling the FRC (FM-).Results:The survey was correctly completed by 76% of participants (892/1173). A total sample of 854 patients (749 in FM+ and 105 in FM-) was analyzed after the exclusion of subjects with major comorbidities. The mean NPSI score was significantly higher in FM+ (56.3/100) respect to FM- (34.2/100). NPSI score was ≥50/100 in 62.4% of FM+ patients and in 21.0% of FM-. More than 3 symptoms indicative for SFP were found in 51% of FM+ patients and in 15.2% of FM-. Dry eyes/mouth, allodynia and changed pattern of sweating on body were the 3 most frequently reported symptoms. We found statistically significant strong associations (p<0.001) for the NPSI score with disability (rho=0.53) and pain (rho=0.63), and a moderate correlation with stiffness levels (rho=0.45) and counting of painful sites (rho=0.33). Symptoms indicative for SFP were significantly correlated (p<0.001) with all clinical variables with low grade of association (Cramer’s V orrho<0.30). Although the higher prevalence of neuropathic pain and symptoms potentially indicative for SFPs, electromyography and electroneurography were performed in 40%-44% of cases, and skin biopsy in 1%-2% of the sample, as well as the assumption of gabapentinoids (12.6% in FM+ and 18% in FM-).Conclusion:This findings highlight the importance of neuropathic pain symptoms identification, since we found a high prevalence and a strong correlation with clinical variables in our cohort of FM patients. The assessment of the neuropathic dimension of pain through self-administered questionnaire should be part of the routine clinical practice.References:[1]Wolfe, F., et al., 2011. Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. The Journal of Rheumatology 38, 1113–1122.Disclosure of Interests: :Antonello Viceconti: None declared, Tommaso Geri: None declared, Simone De Luca: None declared, Filippo Maselli: None declared, Alberto Sulli Grant/research support from: Laboratori Baldacci, Marco Testa: None declared, Giacomo Rossettini: None declared


2012 ◽  
Vol 30 (1) ◽  
pp. 91-93 ◽  
Author(s):  
Seema Mishra ◽  
Prakash Choudhary ◽  
Saurabh Joshi ◽  
Sushma Bhatnagar

Small fiber neuropathy typically involves the small diameter nerve fibers, is usually idiopathic, and presents with peripheral pain. It can be excruciatingly painful at times despite the best of treatments. We present the case of a 22-year-old postoperative case of right frontoparietal oligodendroglioma who received multiple drugs for his severe neuropathic pain without significant relief. However, the pain almost completely subsided once flupirtine was added and substituted for some of the currently recommended first-line drugs.


Pain ◽  
2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Chi-Chao Chao ◽  
Ming-Tsung Tseng ◽  
Yea-Huey Lin ◽  
Paul-Chen Hsieh ◽  
Chien-Ho (Janice) Lin ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-3 ◽  
Author(s):  
Maxim Eckmann ◽  
Alexander Papanastassiou ◽  
Mark Awad

Spinal cord stimulators have commonly been used to treat multiple pain conditions. This case report represents a unique case of using multiple spinal cord stimulators for widespread small fiber neuropathy pain. This case report concerns patient JJ who first presented with generalized neuropathic pain. His pain was an intermittent burning, stinging quality that originally focused in both of his feet and progressed to include his legs and arms and eventually involved his entire body. The pain would last moments to hours at least daily. He reported a poor quality of life. He was diagnosed with small fiber neuropathy with anhydrosis, suggestive of idiopathic erythromelalgia. He had a spinal cord stimulator trial involving both cervical and lower thoracic percutaneous leads. After two spinal cord stimulators were implanted, the patient began to report an improvement in pain. The patient continues to report excellent pain relief. The patient uses the stimulator intermittently as needed, in an abortive fashion for pain flares. The patient is very pleased and has increased his activity. He now attends graduate school full time. This case report hopes to illustrate a unique use of multiple spinal cord stimulators in treating widespread neuropathic pain caused by small fiber neuropathy.


2016 ◽  
Vol 12 ◽  
pp. 174480691666628 ◽  
Author(s):  
Daniela M Menichella ◽  
Nirupa D Jayaraj ◽  
Heather M Wilson ◽  
Dongjun Ren ◽  
Kelsey Flood ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document